"there is initial evidence that penetration of trastuzumab into CSF may be facilitated under conditions of an impaired BBB, as is known for meningeal carcinomatosis. We demonstrate further that high levels of trastuzumab can also be achieved by direct application of trastuzumab into the brain using an Ommaya reservoir. Given the increasing use of trastuzumab to treat HER2-overexpressing breast cancer patients in the metastatic and the adjuvant setting, more patients are expected to benefit from this therapy and may experience a considerable survival advantage."
Application of intrathecal trastuzumab (HerceptinTM) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer (2005)
http://www.spandidos-publications.co.../1373/download